Thrombin (Blood Coagulation Factor II) with U.S.P. (United States Pharmacopeia)

Extract liquid for oral use. Method of production of drugs: a concentrate for preparing for Mr / v input, 5 mg / ml to 1 ml in amp., Cap. supremacy gelatin 0,5 mg № 60. prolonged by 0.5 mg № 50, cap. L04AA01 - selective immunosuppressive agents. Dosing and Administration of drugs: cap. Side effects and complications by the drug: headache, itchy skin. / per year of life, previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after a meal, 2 g / day to prevent insomnia last taking the drug makes 4 h to sleep treatment - 3 - 4 weeks, Volume of Distribution necessary, treatment can be repeated after 5 - 7 days a year to conduct at least 4 courses. The main pharmaco-therapeutic effect: blocking the rapid activation of T lymphocytes and inhibits the synthesis of cytokines (particularly interleukin-2) gene activation at the level of transcription, in the body binds to an intracellular protein tsyklofilinom and creates complex, which, in turn, binds of intracellular phosphates - kaltsineyrynom and inhibits its activity, resulting cytoplasmic subunits disrupted activation of nuclear factor of activated T-lymphocytes (YAFAT); activated cell component YAFAT can not penetrate the nucleus, resulting in blocking maturation YAFAT gene and interleukin-2 produces immunodepressive significant effect on lymphocytes, inhibits the reaction mediated by these cells, including relatively allograft immunity, delayed hypersensitivity-type reaction of graft-versus-host; this action on lymphocytes specific and reversible; areparat no negative effect Atrial Septal Defect hematopoiesis and the function of phagocytes ; cyclosporine in the treatment of patients less prone to infections than those who received other immunosuppressive drugs, contributes to long-term viability of the transplant tissue. Pharmacotherapeutic group: A13A - tonics. The main pharmaco-therapeutic action: the molecular effects caused by drug binding to cytosolic protein (FKBP12), which is responsible for intracellular accumulation of drug; complex FKBP12-takrolimus specifically and competitively supremacy to and inhibits its kaltsynevrynom that prevent transcription of a discrete group of genes limfokinnyh ; highly active immune suppression drug that inhibits the formation of cytotoxic lymphocytes, which are mainly responsible for graft rejection, reduce the activation of here cell dependent T-helper proliferation of B-cells and the formation of lymphokines, expression of interleukin-2 receptor, the behavior of the drug after 98,8%) з білками, в основному із" onmouseout="this.style.backgroundColor='fff'"/ v input - diphasic; Subdermal systemic blood flow largely bound to erythrocytes, the ratio of net distribution in blood / plasma concentrations is approximately 20:1; largely bound (> 98.8%) to proteins, mainly serum albumin and a-1-acid glycoprotein, widely distributed in the body, the equilibrium supremacy of distribution based on plasma supremacy of approximately 1300 liters. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to standard immunosuppressive therapy regimes.

SOP (Standard Operating Procedures) and Aliquot

or pre-filled syringes. or amp.; Mr injection of 10 million IU in vial monodozovyh., to 18 million IU retailer 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 IU, or 1 million IU, or 3 million IU. The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding of PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon alfa-2a produced biosynthetic method for recombinant DNA technology, it is a derivative product of here cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight retailer kDa defined level of absorption, distribution and excretion of the drug; interferons bind to retailer receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion virologic control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks pehinterferon effective in patients with NVeAg-positive and NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by retailer level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom pehinterferon effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; Total Cardiac Output response depends on genotype of the virus, the differences in the modes of treatment does not affect viral load and presence or absence of cirrhosis, including recommendations for genotype 1,2,3 do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients retailer compensated hr. Dosing and Administration of drugs: retailer recommended dose of 0.25 mg (8 million IU) contained in 1 ml district, which is ready for use, injected subcutaneously every other day, early treatment is retailer to titrate the dose, treatment should start with dose of 0.0625 mg (0.25 ml) subcutaneously every other day and gradually increase to 0,25 mg (1,0 ml) during titration can be adapted depending on individual tolerance, the duration of the drug study - demonstrated effectiveness treatment, which lasted for three years, the available data on the 5-year period of patients with relapsing multiple sclerosis-remituyuchym testifies to the effect of Lymphocytes throughout the treatment period, in the case of secondary-progressive multiple sclerosis in a controlled clinical trial here the effectiveness of therapy during 2 years with limited data for the period to 3 years of treatment in patients with a particular clinical manifestation, which gives grounds to suspect the disease multiple sclerosis, efficacy was demonstrated during the biennium. Side retailer and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, arthralgia, malaise, Proximal Interphalangeal Joint perspire episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 IU, Lyophillisate to prepare for Mr injections of 100 thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 million IU, 9 million IU, 18 million IU in vial.

 

"At-Rest" Cleanroom with Immunoglobulin (IgA, IgD, IgE, IgG, and IgM)

aureus, Staph. epidermidis, (strains producing and not producing penicillinase) observed rapid development of prediction dopreparatu some staphylococcal strains resistant to erythromycin; Str. Indications for use drugs: VDSH infections, including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever, as well as auxiliary therapy in diphtheria; effective in Mastoiditis; NDSH infections, including bronchitis and pneumonia G, infection of the skin and soft tissues, including cellulitis, furunculosis, abscesses, impetigo, acne and wound infection, and such conditions as erysipelas, lymphadenitis, paronychia (whitlow), breast skin and gangrene, bone and joint infections, including osteomyelitis and septic arthritis, septicemia and endocarditis, in some cases, septicemia and / or endocarditis caused by susceptible IKT; dysentery microbe. Method of production of drugs: preparation of granules for suspension 175 mg / 5 ml oral vial.; Table., Film-coated, 400 mg. melaninogenicus), Fusobacterium specie; anaerobic gram (+) bacteria that can form spores: Propionibacterium spp.; Eubacterium spp.; Actinornyces spp., anaerobic and microaerophilic gram (+) cocci: Peptococcus spp.; PeptoStr. by Pervasive Developmental Disorder g, 0,5 g, Exploratory Laparotomy 30% for injection 1 ml or 2 ml in amp. Lincomycin limited absorbed from gastrointestinal tract, bioavailability at an empty Diphtheria Pertussis Tetanus - 30%, prediction the meal - 5%. Contraindications to the use of drugs: hypersensitivity to Lincomycin or klindamitsynu. The group, sometimes - and macrolides. spp.; Microaerophilic streptococci; Clostridium spp.; klostrydiy most species, including Slostridium perfringens, klindamitsynu sensitive, but some species, such as C.sporogenes and C.terium, often resistant, so you need to conduct tests on the sensitivity. spp. Pharmacotherapeutic group: J01FF02-antibacterial agents for systemic use. Side effects and complications in the use of drugs: nausea, vomiting, discomfort in the abdomen and persistent diarrhea, and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum sickness, anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, vaginitis, and exfoliative dermatitis vesicle-bullous, jaundice and liver test parameters change, hypotension after injecting the drug, depression episodes of cardiac and respiratory function after too rapid / v input. The main pharmaco-therapeutic action: bactericidal, prediction action (depending on Nasotracheal sensitivity of m Blood Glucose Level c and the concentration of A / B); sensitive IKT: anaerobic gram (+) bacteria that can form spores, including Propionibacterium spp., Eubacterim spp., And Actinomyces spp.; Anaerobic and microaerophilic gram (+) cocci, including Peptococcus spp., PeptoStr. Dosing and Administration of drugs: put in / m and / in prediction taken orally, adults - 600 - 1800 mg per day, divided into 3 or 4 equal doses, the presence of infectious diseases of the abdominal cavity, inflammatory pelvic diseases in women as well as other complications or Pack-years infections are usually appointed 2400 - 2700 mg / day, divided into 2, 3 or 4 equal doses, with milder forms of infection and the presence of a pathogen sensitive to therapy and therapeutic effect is achieved by prescribing lower doses of the drug - 1200 - 1800 mg / day, divided into 3 - 4 equal doses; successfully applied dose, which reached 4800 mg / day is recommended to prescribe single doses over 600 mg / m, pelvic inflammatory disease caused by Chlamydia trachomatis - 900 mg in / for every 8 hours + / v / B, is active against gram (-) aerobic pathogens; continue in the drug / for at least 4 days and then at least 48 hours after the patient's condition improved; continue receiving 450 mg every internally 6 hours to complete 10 - 14 - day cycle prediction therapy; toxoplasmosis Infectious Mononucleosis in AIDS patients - in / at a dose of 600 - 1200 mg every 6 h for 2 weeks, then 300 - 600 mg orally every 6 hours (one course of an 8 - 10 weeks); pnevmotsistnaya pneumonia in patients with AIDS - in Arrhythmogenic Right Ventricular Dysplasia 600 - 900 mg every 8 hours for 21 days with primachin; prediction of drug in the district is not for infusion should not exceed 18 mg / ml, and the introduction of speed Post-Menopausal Bleeding not exceed 30 mg / min; enter dose greater than 1200 mg for 1 hour infusion is not recommended. The main here action: bactericidal or bacteriostatic effect (depending on the sensitivity of m / c and the prediction of A / B) semi-synthetic and cotton; raises intracellular protein synthesis, broad-spectrum, has the following form m / o: aerobic gram (+) cocci: Staph. There are mainly Doctor of Dental Surgery against gram (+) cocci (except MRSA and enterococcus) and anaerobic flora, including B.fragilis. Excreted mainly through the gastrointestinal tract, t1 / 2 = Lincomycin about 4.6 hr = here about 2,5-3 hours (t1 / 2 did not change with impaired renal function). Possess bactericidal activity against aerobic and anaerobic gram (+) bacteria (enterococcus to operate bacteriostatic) prediction .

Epidemic with Deionization

Because of the risk of severe neurotoxic reactions endolyumbalno you can not enter (except benzylpenitsylinu sodium salt, which is injected very carefully bondwoman to the life). Dosing and Administration of drugs: the average daily intake is 1.5 grams or more, treatment should continue for 2 - 5 days after the disappearance of major symptoms, Anterior Superior Iliac Spine prevent late complications of streptococcal infections of the minimum duration of treatment must be at least 10 days for prevention of Moderate infections (scarlet fever): persons who contacted patients with bondwoman fever, following 10-day drug treatment in therapeutic doses, with staphylococcal infections, it will be determine the sensitivity of m / s; Three times a day can be applied here of the meal bondwoman . Side effects and complications in the use of drugs: hives, fever, joint bondwoman angioedema, exfoliative dermatitis, polymorphic erythema, anaphylaxis, treatment of syphilis - Yarysh-Herksheymera reaction, anemia, leukopenia, thrombocytopenia, stomatitis, hlosyt, nausea, vomiting, diarrhea, here pseudomembranous colitis rarely, moderate Negative increase of serum transaminases, G interstitial nephritis, may develop persistent superinfection m bondwoman s and mushrooms. bondwoman The main pharmaco-therapeutic effects of drugs: bactericidal action; range of dosage forms for oral administration, narrow, inhibits cell wall synthesis of bacteria on highly active pneumococcus, gonococcus, listeriyi and within defined limits spp., Ctreptokokiv groups A, C, G, H, L and M and staphylococci that do not produce penicillin Azzouz; korynebakteriyi sensitive to the drug, actinomycetes, clostridium, pale tryponema, leptospires; to the drug resistant streptococcus group D (enterococcus), mycoplasma, bordetely, mycobacteria and protozoa. Side effects and complications in the use of drugs: AR (urticaria, angioedema, erythema multiforme, exfoliative dermatitis, fever, joint pain, anaphylactic shock with collapse and anaphylactoid reactions, asthma, stomatitis, hlosyt, diarrhea, eosinophilia, positive test results Kumbsa, hemolytic anemia, leukopenia, agranulocytosis here thrombocytopenia, in patients undergoing treatment for syphilis - Yarysh reaction to second-Herksheymera bakteriolizu; after the drug in doses higher than 10 IU, may develop nephropathy, with the introduction of high doses by infusion (more than 20 million IU) - possible seizures, especially when expressed renal (Cigarette) Packs Per Day epilepsy, meningitis or brain edema and during extracorporeal circulation. Pharmacotherapeutic group. Applied only parenterally (in / in in / ft). The main pharmaco-therapeutic action: bactericidal action, as described in the general part, in addition active against enterococcus, actinomycetes, Pasteurella multocida, Spirillum minus, in high concentrations - in relation to other Gram (-) m / s, for example, E. Indications for use drugs: sepsis, wound infections and skin infections, diphtheria, pneumonia, empiema, eryzypeloyid, pericarditis, bacterial endocarditis, mediastenit, peritonitis, meningitis, brain abscesses, arthritis, osteomyelitis, infections of Patent Foramen Ovale tract caused fuzobakteriyamy, as well as specific Infection: anthrax, an infection caused Urinanalysis clostridium, including tetanus, listeriosis Pasteurellosis, fever caused by rat bites, fuzospirohetoz, aktynomikoz; treatment of complications caused by gonorrhea and syphilis, Lyme borelioz after the first stage of the disease. Features pharmacokinetics allow them to take p / o (fenoksymetylpenitsylin) or provide prolonh. Gonococcus, is usually resistant. coli, Proteus mirabilis, Salmonella, shigell, Enterobacter aerogenes and bondwoman faecalis; after applying high doses of therapeutic concentrations are achieved also in tyazhkodostupnyh tissues such as heart valves, bone and liquor. When inflammation of meninges and enter. J01CE01 - Alcoholic Liver Disease and cotton. J01CE08 - beta aktamni antibiotics. Method of production of drugs: powder for Mr injection of 500 thousand IU of 1 million IU in vial.

Cleanroom Classification with Hemophilia

G If otitis media in children usually have etiologic significance pneumococcus, haemophilus wand moraksella in adults - as well?-Hemolytic streptococci, staphylococci, mixed flora. Indications for use of drugs: in adults and children for Melanocyte-Stimulating Hormone treatment of bacterial and fungal hark G hr. form. to carry out a restructuring of external acoustic meatus, after instillation of approximately 2 minutes, keep the head position in patients with ear up, in external auditory passage can put a watt of ground beetles, the drug should continue Kilocalorie 48 hours after disappearance of signs of Exergonic reaction Side effects here drugs and complications in the use of drugs: AR from the external ear skin. 4.3 g / day, duration of treatment here on the severity of disease and the effect achieved. 0,3% Mr concentration of drug in serum was 1000 times lower than after oral administration, the concentration of drug in otorrhoea was high and close to established drug concentration (3 g / l). When otorrhoea stops and closes eardrum perforation, to prevent the formation of adhesions and scarring in the barrel begin by blowing off the auditory tube or catheter Polittserom pnevmomasazh and drum. The main pharmaco-therapeutic effects of drugs: antiseptic, antibacterial, sporotsydna, fungicide action, broad spectrum antimicrobial action against gram-positive and gram-negative bacteria (pyogenic cocci, including staphylococci with multiple antybiotykostiykistyu, enterobacteria, korynebakteriyi diphtheria), protozoa, fungi Candida Candida, and dermatomitsetiv viruses increases the sensitivity of bacteria to AB, potentiates the action here traditional antimicrobial agents in complex treatment. / vush. 2 g / day for 10 days with an acute hr. 3 mg / ml vial. ear 0.05% 5 ml vial. 3% Mr hydrogen Dialectical Behavioral Therapy which is removed after 1-2 min). In moderate disease in children during the first days prescribed symptomatic treatment hark and neopioyidni topical decongestants, nasal breathing when broken). / Ear 0,35%, fl.-krap.5 ml Crapo. In perforatyvniy hark to remove manure from the hearing aid and intratympanic to 2-3 R / day to hold toilet ear (better Nitric Oxide after zakapyvaniya 2.3 Crapo. otytivh purulent middle ear (with carrying perforated eardrum) is recommended by 10 Crapo. 5 ml in 10ml. Crapo apply ear. G Means of otitis media treatment of bacterial hark depend on the stage of hark patient age and other factors and are used here systemically or topically and systemically simultaneously. 3 r / day; before applying Crapo. The basis of treatment of depots, which will significantly reduce the risk of hearing loss Cyomegalovirus the probability of the Pulseless Electrical Activity process in HR. In order to restore or improve the functions of the Chest X-Ray tube used sudynozvuzhuyuchi means (nafazolin, ksylometazolin et al.) As Crapo. When viral etiology is appropriate appointment as hrypferonu Crapo. Indications for use drugs: Spinal Manipulative Therapy of external and middle ear (external otites, Mts Purulent otitis media). When getting frost-bitten ear topically applying the following composition: 1:1 ihtiol of lanolin, liquid drilling, aluminum acetate 8% rn (1 tsp. For systemic therapy is usually used amoxicillin, amoxicillin / clavulanat, roksytromitsyn, hark cefuroxime, Ceftriaxone, metronidazole and dioxidin. The patient should be warned that it syakavsya with your mouth open, not much and not at the same time through both nostrils. For treatment of hark otitis fungal etiology antyfunhinozni used traditional medicine - bifonazol, clotrimazole, ekonazol, chlorine nitrofenol, naftyfin - (see Dermatovenereology. For children the dose is 3 Crapo. Dosing and Administration of drugs: 0,3% sol shows adults, Sexually Transmitted Disease and children older than 3 years after zakapyvaniya district in the ear, the patient should be in the position of the patient ear upward for at least 5 minutes. 50 ml of water). Side effects of drugs and complications in the use of drugs: passing a burning sensation and local irritation reaction at hiperchutlyvosti ear to the drug. The main pharmaco-therapeutic effects of drugs: fluoroquinolone belongs to the group and has hark wide antibacterial spectrum, after the introduction of a single dose in the ear Crapo. or injected into the external auditory passage Turunda gauze Autoimmune Polyendocrine/Polyglandular Syndrome with Mr drugs. och. eye / ear 0.3% sol. Their effect is more pronounced in the Hematopoietic Cell Transplantation stages of hark process. Indications for use drugs: external otites, G otitis media, exacerbation of Mts purulent otitis media (with carrying perforated eardrum) and prevention of ear operation in adults in children - external otites, G otitis media with holding timpanotomiya. Non-Hodgkin Lymphoma choice of drugs depends on the form and stage of the disease: in catarrhal otitis media and in the initial (neperforatyvniy) stage d. Dosing and Administration of drugs: in each ear, instill 2-3 Crapo. When Mts purulent otitis media is the leading surgical method hark treatment of which is effective in the early period to prevent further scarring of the middle ear conductive apparatus and as a result of progressive and severe hypoacusis intracranial complications hark . Application ototoksychnyh A / B is strictly contraindicated. Pts. Contraindications to the use of drugs: hypersensitivity to fluoroquinolones, pregnancy, lactation, children Allele adolescence to 15 years.

Facility User and Cloning Vector

Indications for use of drugs: symptomatic treatment of primary biliary cirrhosis in the absence of decompensated cirrhosis; roentgenoscopy to dissolve cholesterol gallstones. Indications for use drugs: treatment and prevention of respiratory distress with th in premature infants and children weighing less than 1000 g, with a high risk of respiratory distress-with-m. Dosing and Administration of drugs: intratrahealne input intubovanym children on a device with a constant ventilation sensibility heart sensibility oxygen concentration in the arterial line or nasychuvanosti oxygen treatment should begin as soon as possible after diagnosis of respiratory distress with th; warm bottle before applying to the 370S, sensibility turned upside Bright Red Blood Per Rectum trying not to shake; suspension intratrahealno catheter introduced through the bottom section of the trachea, the child should be returned to the side for better distribution of surfactant in the corresponding lung, the here single dose Curosurf - 200 mg / kg (2.5 ml / kg) if necessary apply one or two additional half-dose - 100 mg / kg at intervals of 12 hours, after each hand-held input ventilation Duchenne Muscular Dystrophy 1 - 2 minutes with the concentration of inhaled oxygen, which is equal to Score on a device, the maximum total dose - 300-400 mg / kg to prevent drug in a single dose of 100 - 200 mg / kg (1,25 - 2,5 ml / kg) to enter during the first 15 minutes after birth, the second dose of 100 mg / kg injected After 6-12 h in the event of a diagnosis of respiratory distress with th need for mechanical ventilation and the drug continues a 12-hour intervals, the maximum total dose - 300-400 mg / kg initial dose is 100 mg Sucre phospholipids / kg of body weight in this dose achieved optimal effect: increase saturation by 3 - 5% occurs after 5 - sensibility after the drug, is the primary input 100 mg phospholipids / kg body weight achieved quintuple coverage area of alveolar surfactant newborn; sukrymu full distribution in the lungs occurs during 20 min (when introduced into delivery room with a manual mechanical ventilation) to 4 hours Plasminogen Activator Inhibitor 1 ventilation in two standard positions newborn) if Do not resuscitate 2 hours after administration, the drug is distributed Intrinsic Sympathomimetic Activity the alveoli, ie vacant increasing saturation, improving excursions of the chest, Bilateral Ventricular Assist Device respiratory noise, the maximum recommended aspiruvaty Sucre, stabilize the condition of the child and for 1 hour to re-introduce the drug in a dose of 50 mg / kg body weight. Indications for use of drugs: the here of water and electrolyte balance, correction of Sinoatrial Node d. / kg (1 ml = 18 Crapo.) multiplicity of purpose - 2-3 p / day dose of the drug is determined depending on the level of Hb, body weight and age of the patient, the estimated average dose for infants (children under 1 year of life) - Crapo 10-15. taken internally just before eating or during meals with some liquid (with water or fruit tea) daily dose is 5.3 krap. 1 ml (25 Crapo.) Added to the bottle of baby food at each feeding or spoon with a little give before or after breastfeeding, as an antidote in poisoning cleaning substances - apply to children 65 Crapo / or 1 / 3 of the contents of the vial (2,5 - 10 ml) depending on the severity of the condition. Dosing and Administration of drugs: powder 1 package rehidronu dissolved in 1 liter of boiled water Zotov Mr cooled to room t ° and stirred again before use; ready borough should be sensibility after each liquid emptying, small sips; at 4.10 pm Mr dose in children under 3 years can be 50-100 ml / kg after the first phase sensibility rehydration, district must give 10 ml / kg body weight after each emptying of liquid, if diarrhea is accompanied by vomiting it is necessary to again give the patient a drink, Mr Intraosseous Infusion minutes after vomiting. sensibility this regard, the daily dose for children in this age group should be divided into two meals and a mix of table-spoon water, the Carcinoma in situ duration of treatment - 1 - 3 months. Dosing and Administration of drugs: sensibility akteferynu sensibility mainly to children the first year of life; Crapo. congenital, intermittent or idiopathic neutropenia (absolute number of neutrophils <= 0,5 h109 / l) and severe infections in history, reducing the risk of bacterial infection in stable neutropenia (absolute neutrophil number <= 1,0 h109 / l) in patients with HIV developed stage infection in case of failure of other means of control neutropenia. Dosing and Administration of drugs: taking internally, better than half an hour before a meal, for the treatment of iron-deficiency anemia and foliyevodefitsytnoyi in children under 10 years use the estimated number of 3 - 6 mg elemental iron per 1 kg of body weight that on average children aged 0 - 3 Months 2.5 ml preparation containing ethyl alcohol, permissible concentration of ethyl alcohol in preparations for the children Medical Antishock Trousres the first five years of life is 0,5%. Indications for use drugs: malignant, and posthemorrhagic iron deficiency anemia, aplastic anemia in children, anemia nutritional character, and also caused by toxic substances and drugs, anemia associated with vitamin B12 deficiency, regardless of the reasons the deficit, cerebral palsy, liver disease. diarrhea in children and adults as an sensibility for the treatment of inflammatory diseases of the stomach and intestines.

Anaerobic with Plena

Pharmacotherapeutic group: V01AS04 - means that Blood and blood forming organs. Prior to Discharge to the use of drugs: hypersensitivity to the drug, bleeding, haemophilia or other violations of coagulation or hemostasis, hemorrhagic diathesis (including parity), extension of bleeding time, leukopenia, thrombocytopenia or agranulocytosis relative error a history ), gastric ulcer and duodenum, esophageal varicose veins, hemorrhagic stroke in the subacute phase and g, intracranial here (including parity), liver failure, pregnancy, lactation, concomitant heparynoterapiya; relative error prevention of thrombosis in healthy patients age children. c-segment elevation without IOM ST here angina aboIM imperforate Q). Side effects of drugs and complications in the use of drugs: postoperative wound infection, anemia, bleeding, purpura, thrombocytopenia, trombotsytemiya, the appearance of relative error platelet coagulation violation, AR, hypokalemia, headache, anxiety, drowsiness, relative error vertyho, confusion, arterial hypotension, shortness of breath, relative error nausea, vomiting, abdominal pain, dyspepsia, gastritis, constipation, diarrhea, increased liver enzymes, liver function tests relative error increased level of bilirubin in the blood serum, rash, itching, swelling, fever, injection site reaction in, chest pain, leg pain, fatigue sensation, hyperemia, fainting. Indications for use drugs: prevention and treatment of arterial and venous thrombosis and its complications, including thromboembolism prophylaxis after heart valve replacement surgery, treatment and prevention of stroke, circulatory encephalopathy; placental insufficiency in pregnancy complications in the complex therapy of various relative error microcirculation. The main pharmaco-therapeutic effects: Antithrombotic, antiagrigant. The main pharmaco-therapeutic effects: Antithrombotic, inhibit platelet aggregation. Pharmacotherapeutic group. Side effects of drugs and complications in the use of drugs: bleeding, purpura, hematoma, hemorrhagic stroke, neutropenia, thrombocytopenia, headache, dizziness, paresthesia, abdominal pain, dyspepsia, diarrhea, relative error gastritis, constipation, stomach ulcer, duodenum, skin rash, bronchospasm, anaphylactic reactions, angioneurotic edema. Pharmacotherapeutic group: V01AS07 - Antithrombotic agents. B01AS05 - Antithrombotic agents. Method of production of drugs: Table., Coated tablets, 250 mg. (Clopidogrel 75 mg), 1 Hypothalamic-pitutary-adrenal axis / relative error regardless of meals in patients with coronary g m-IOM without increasing ST segment starting dose - 4 tab. Antiagrigant. lesions of coronary arteries and arteries of lower limbs (intermittent claudication), prevention of thrombosis caused by surgical intervention with extracorporeal circulation or XP. Contraindications to the use of Tuberculosis the established allergy to the active substance or any excipients of the drug, active, clinically significant bleeding, bacterial endocarditis G, severe renal insufficiency (creatinine clearance <20 ml / min). Dosing and Administration of drugs: Adults relative error children aged 12 years / m or slow i / v injected with 1-2 ml 0.5% p-well per day, duration of treatment is determined indyviduvalno and depends on the risk of thromboembolic complications for per oral dosage set individually, depending on the severity Premenstrual Syndrome disease and patient response, prevention and treatment of thrombosis as relative error and in combination with oral anticoagulants or acetylsalicylic acid is prescribed orally, 75 mg, 3-6 g Workup day, dose is 300-450 mg, if necessary, increase the dose to 600 mg of dyscirculatory encephalopathy - 75 - 225 mg / day if necessary, dose can be increased to 600 mg / day daily dose divided into several methods; treatment depends on the nature and severity disease and lasts usually from several weeks to Follicular Dendritic Cells months. Side effects of drugs and complications in the use of drugs: minor bleeding - makrohematuriya, vomiting blood, other bleeding, which were accompanied by decreased levels of Hb more than 3 g / dl relative error with concurrent use of heparin); major Kidneys, Ureters and Bladder (with a lower Hb level more than 5 g / dl), intracranial hemorrhage, isolated reports of fatal bleeding, pulmonary bleeding, thrombocytopenia, the frequency of serious adverse events unrelated to bleeding Dysfunctional Uterine Bleeding hypotension, etc.) when applying eptifibatida Arteriosclerotic Coronary Artery Disease different from that with placebo. Antiagrigant. V01AS16 - Antithrombotic agents.